Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 77-85, 2008. First published November 16, 2007; 10.1373/clinchem.2007.089896
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.089896v1
54/1/77    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Narasipura, S. D.
Right arrow Articles by King, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Narasipura, S. D.
Right arrow Articles by King, M. R.
Related Collections
Right arrow Hematology
(Clinical Chemistry. 2008;54:77-85.)
© 2008 American Association for Clinical Chemistry, Inc.


Hematology

P-Selectin–Coated Microtube for Enrichment of CD34+ Hematopoietic Stem and Progenitor Cells from Human Bone Marrow

Srinivas D. Narasipura1, Joel C. Wojciechowski1,3, Nichola Charles1, Jane L. Liesveld2 and Michael R. King1,a

1 Department of Biomedical Engineering, 2 Department of Medicine, Wilmot Cancer Center, University of Rochester, 3 CellTraffix Inc, Rochester, NY.

aAddress correspondence to this author at: Department of Biomedical Engineering, University of Rochester, Room 218, Goergen Building, Rochester, NY 14627. Fax 585-276-1999; e-mail mike_king{at}urmc.rochester.edu.

Background: Enrichment and purification of hematopoietic stem and progenitor cells (HSPCs) is important in transplantation therapies for hematologic disorders and in basic stem cell research. Primitive CD34+ HSPCs have demonstrated stronger rolling adhesion on selectins than mature CD34 mononuclear cells (MNCs). We have exploited this differential rolling behavior to capture and purify HSPCs from bone marrow by perfusing MNCs through selectin-coated microtubes.

Methods: Bone marrow MNCs were perfused through the cell-capture microtubes coated with adhesion molecules. We washed the device lumen and visualized and estimated captured cells by video microscopy. Adherent cells were eluted by high shear, calcium-free buffer, and air embolism. We used immunofluorescence staining followed by flow cytometry to analyze CD34+ HSPCs.

Results: CD34+ HSPC purity of cells captured in adhesion molecule–coated devices was significantly higher than the fraction of CD34+ cells found in bone marrow MNCs [mean (SE) 2.5% (0.8%)]. P-selectin–coated surfaces yielded 16% to 20% CD34+ cell purity, whereas antibody-coated surfaces yielded 12% to 18%. Although CD34+ cell purity was comparable between selectin and antibody surfaces, the total number of CD34+ HSPCs captured was significantly higher in P-selectin devices (approximately 5.7 x 104 to 7.1 x 104) than antibody devices (approximately 1.74 x 104 to 2.61 x 104).

Conclusions: P-selectin can be used in a compact flow device to capture HSPCs. Selectin-mediated capture of CD34+ HSPCs resulted in enrichment approximately 8-fold higher than the CD34+ cell population from bone marrow MNCs. This study supports the hypothesis that flow-based, adhesion molecule–mediated capture may be a viable alternative approach to the capture and purification of HSPCs.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Cancer Res.Home page
M. Bazzaro, Z. Lin, A. Santillan, M. K. Lee, M.-C. Wang, K. C. Chan, R. E. Bristow, R. Mazitschek, J. Bradner, and R. B.S. Roden
Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
Clin. Cancer Res., November 15, 2008; 14(22): 7340 - 7347.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.